Establishment of an in vivo murine model of immune checkPoint inhibitors cardiotoxicity: emerging role of vascular permeability in pembrolizumab-induced cardiotoxicity.

25 August 2023 (07:30 - 18:30)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Panagiotis Efentakis

National & Kapodistrian University of Athens, Athens (Greece)

5 More presentations in this session

Presentation thumbnail

Mitochondrial dynamics and myocardial metabolism alterations during anthracycline-cardiotoxicity

Miss A. Diaz-Guerra Priego (Madrid, ES)

Abstract Slides Video

Presentation thumbnail

Cardioprotection beyond the guidelines: the SAFE trial results

Doctor G. Barletta (Florence, IT)

Abstract Slides Video

Presentation thumbnail

Adult survivors of childhood cancer have significant levels of impaired cardiorespiratory fitness, inflammatory markers and poor quality of life outcomes

Doctor C. McCune (Belfast, GB)

Abstract Slides Video

Presentation thumbnail

Association between vitamin D receptor gene polymorphism and cardiomyopathy in response to adriamycin treatment among breast cancer patients

Miss R. Mokhtar (Cairo, EG)

Abstract Slides Video

Presentation thumbnail

Association between immune checkpoint inhibitors and heart failure hospitalizations: a population-based self-controlled case series

Professor G. Tse (Hong Kong, CN)

Abstract Slides Video

Access the full session

Session thumbnail

Cardiotoxicity of cancer therapies

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023

You may be interested in

Congress Presentation

Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.

Congress Session

Chronic kidney disease and heart failure

Congress Session

Rare causes of heart failure

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources